Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Oncogene (20)
Cell Death and Differentiation (15)
Nature (13)
Bone Marrow Transplantation (4)
Nature Medicine (4)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (58)
Reviews (7)
Amendments and Corrections (3)
News & Views (3)
Comments & Opinion (1)
Correspondence (1)
Editorial (1)
Protocols (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Biophysics
Cancer
Cell biology
Computational biology and bioinformatics
Developmental biology
Diseases
Drug discovery
Genetics
Health care
Immunology
Materials science
Medical research
Molecular biology
Neuroscience
Oncology
Pathogenesis
Physiology
Systems biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 75 results

Advanced filters: Author: Moshe Oren Clear advanced filters

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

Elisheva Yonish-Rouach
Dalia Resnftzky
Moshe Oren
Research25 Jul 1991
Nature

Volume: 352, P: 345-347
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins

Orit Pinhasi-Kimhi
Dan Michalovitz
Moshe Oren
Research13 Mar 1986
Nature

Volume: 320, P: 182-185
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

Daniel Eliyahu
Avraham Raz
Moshe Oren
Research13 Dec 1984
Nature

Volume: 312, P: 646-649
Mdm2 promotes the rapid degradation of p53

Ygal Haupt
Ruth Maya
Moshe Oren
Research15 May 1997
Nature

Volume: 387, P: 296-299
A single gene and a pseudogene for the cellular tumour antigen p53

Rina Zakut-Houri
Moshe Oren
David Givol
Research08 Dec 1983
Nature

Volume: 306, P: 594-597
T–T cell collaboration in rejection of a syngeneic SV40-induced sarcoma in mice

MOSHE GLASER
LLOYD W. LAW
Research01 Jun 1978
Nature

Volume: 273, P: 385-387
Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia

Michelle M. Le Beau
Carol A. Westbrook
Moshe Oren
Research29 Aug 1985
Nature

Volume: 316, P: 826-828
ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response

Lim, Adler et al. show that the urea cycle enzyme ASS1 can function in the nucleus to supply fumarate necessary to drive DNA damage responses.

Lisha Qiu Jin Lim
Lital Adler
Ayelet Erez
ResearchOpen Access10 Jun 2024
Nature Metabolism

Volume: 6, P: 1294-1309
Induction of Mdm2 and enhancement of cell survival by bFGF

Eitan Shaulian
Dalia Resnitzky
Moshe Oren
Research27 Nov 1997
Oncogene

Volume: 15, P: 2717-2725
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

Tanya M Gottlieb
Juan Fernando Martinez Leal
Moshe Oren
Research20 Feb 2002
Oncogene

Volume: 21, P: 1299-1303
The first 30 years of p53: growing ever more complex

When p53 was first discovered, it received relatively little attention from cancer researchers. The road leading to p53's rise to fame, and the recognition ofTP53as the most frequently altered gene in human cancer, has been long and winding. This Timeline examines the rich history of this pivotal tumour suppressor.

Arnold J. Levine
Moshe Oren
Reviews01 Oct 2009
Nature Reviews Cancer

Volume: 9, P: 749-758
Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs

Yingcai Wang
Giovanni Blandino
David Givol
Research14 Oct 1998
Oncogene

Volume: 17, P: 1923-1930
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage

Nobuyuki Tanaka
Masahiko Ishihara
Tadatsugu Taniguchi
Research29 Aug 1996
Nature

Volume: 382, P: 816-818
Thiamin Status of the Offspring of Diabetic Rats

Moshe Berant
Drora Berkovitz
Daniel Mordohovich
Research01 Jun 1988
Pediatric Research

Volume: 23, P: 574-575
Inhibition of presenilin 1 expression is promoted by p53 and p21^WAF-1and results in apoptosis and tumor suppression

Jean-Pierre Roperch
Véronique Alvaro
Adam Telerman
Research01 Jul 1998
Nature Medicine

Volume: 4, P: 835-838
The legacy of a gentleman scientist: Pierre Hainaut

Christophe Arnoult
Laura D. Attardi
Daniel Schramek
Comments & OpinionOpen Access03 Oct 2025
Cell Death & Differentiation

P: 1-2
Author Correction: Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis

Yael Aylon
Noa Furth
Moshe Oren
Amendments and CorrectionsOpen Access10 Jan 2023
Nature Communications

Volume: 14, P: 1
Involvement of p21^WAF1/Cip1, CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition

Ayelet Zauberman
Moshe Oren
Dov Zipori
Research02 Oct 1997
Oncogene

Volume: 15, P: 1705-1711
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity

Tamar Unger
Ronit Vogt Sionov
Ygal Haupt
Research25 May 1999
Oncogene

Volume: 18, P: 3205-3212
Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis

LATS1 is reported to regulate the transition of luminal-basal-like cell plasticity in breast cancer. Here the authors report that LATS1 limits the progression of luminal breast cancer by associating with NCOR1 nuclear corepressor to repress ERα-downregulated genes in luminal cells.

Yael Aylon
Noa Furth
Moshe Oren
ResearchOpen Access28 Nov 2022
Nature Communications

Volume: 13, P: 1-20
The loss of mdm2 induces p53 mediated apoptosis

Sohela de Rozieres
Ruth Maya
Guillermina Lozano
Research29 Mar 2000
Oncogene

Volume: 19, P: 1691-1697
Comparative community genomics in the Dead Sea: an increasingly extreme environment

Idan Bodaker
Itai Sharon
Oded Béjà
Research24 Dec 2009
The ISME Journal

Volume: 4, P: 399-407
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients

The differential effects of TP53 missense mutations in colorectal cancer (CRC) remain to be explored. Here the authors compare the gain of function impact of two frequent TP53 mutations in CRC and show that p53R273 mutants control a transcriptional program, which drives oncogenic signaling pathways, leading to a more aggressive phenotype and worse patient outcome.

Ori Hassin
Nishanth Belugali Nataraj
Moshe Oren
ResearchOpen Access19 May 2022
Nature Communications

Volume: 13, P: 1-15
p53 mutations promote proteasomal activity

p53 mutations occur very frequently in human cancer. Besides abrogating the tumour suppressive functions of wild-type p53, many of those mutations also acquire oncogenic gain-of-function activities. Augmentation of proteasome activity is now reported as a common gain-of-function mechanism shared by different p53 mutants, which promotes cancer resistance to proteasome inhibitors.

Moshe Oren
Eran Kotler
News & Views27 Jul 2016
Nature Cell Biology

Volume: 18, P: 833-835
Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

A multi-modal analysis of pre-metastatic liver biopsies from patients with localized pancreatic cancer with a minimum of 3 years of follow-up shows that immunological, proliferative and metabolomic features distinguish patients who develop metastases from disease-free survivors and can be used to predict outcomes.

Linda Bojmar
Constantinos P. Zambirinis
David Lyden
Research28 Jun 2024
Nature Medicine

Volume: 30, P: 2170-2180
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential actionable targets.

Yael C. Cohen
Mor Zada
Ido Amit
Research22 Feb 2021
Nature Medicine

Volume: 27, P: 491-503
Attenuation of the p53 response to DNA damage by high cell density

Jair Bar
Efrat Cohen-Noyman
Moshe Oren
Research02 Feb 2004
Oncogene

Volume: 23, P: 2128-2137
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Giovanni Blandino
Arnold J Levine
Moshe Oren
Research20 Jan 1999
Oncogene

Volume: 18, P: 477-485
Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila

Adriana Folberg-Blum
Amir Sapir
Moshe Oren
Research16 Apr 2002
Oncogene

Volume: 21, P: 2413-2417
Interaction of c-Abl and p73α and their collaboration to induce apoptosis

Reuven Agami
Giovanni Blandino
Yosef Shaul
Research24 Jun 1999
Nature

Volume: 399, P: 809-813
Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells

Neri Minsky
Efrat Shema
Moshe Oren
Research16 Mar 2008
Nature Cell Biology

Volume: 10, P: 483-488
Author Correction: ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response

Lisha Qiu Jin Lim
Lital Adler
Ayelet Erez
Amendments and CorrectionsOpen Access04 Jul 2024
Nature Metabolism

Volume: 6, P: 1417
Papillomavirus E2 induces p53-independent apoptosis in HeLa cells

Christian Desaintes
Sylvain Goyat
Françoise Thierry
Research18 Aug 1999
Oncogene

Volume: 18, P: 4538-4545
ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53

Stéphanie Courtois
Gerald Verhaegh
Pierre Hainaut
Research02 Oct 2002
Oncogene

Volume: 21, P: 6722-6728
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

In two mouse models of intestinal cancer, mutant p53 has an oncogenic effect in the distal gut but a tumour-suppressive effect in the proximal gut, and these opposing properties are determined by the gut microbiome.

Eliran Kadosh
Irit Snir-Alkalay
Yinon Ben-Neriah
Research29 Jul 2020
Nature

Volume: 586, P: 133-138
Prokaryote taxonomy online: challenges ahead

Aharon Oren
Erko Stackebrandt
Correspondence05 Sept 2002
Nature

Volume: 419, P: 15
Growth Mechanisms and Electronic Properties of Vertically Aligned MoS₂

Chen Stern
Shmuel Grinvald
Doron Naveh
ResearchOpen Access07 Nov 2018
Scientific Reports

Volume: 8, P: 1-7
Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure

Ruth Maya
Moshe Oren
Research05 Jul 2000
Oncogene

Volume: 19, P: 3213-3215
Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

Amir Zalcenstein
Perry Stambolsky
Moshe Oren
Research28 Aug 2003
Oncogene

Volume: 22, P: 5667-5676
Teaming up to restrain cancer

Tumour-suppressor genes such asp53 serve as potent buffers against uncontrolled cell multiplication and cancer. But it now seems that they do not work alone. Another tumour-suppressor protein, p33^ING1, has been found to form a direct complex with p53. And it seems that each of the proteins requires the other to exert its inhibitory effects.

Moshe Oren
News & Views15 Jan 1998
Nature

Volume: 391, P: 233-234
ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC

Kathrin Böpple
Yaara Oren
Walter E. Aulitzky
ResearchOpen Access24 Apr 2024
Cell Death & Disease

Volume: 15, P: 1-12
Drugging p53 in cancer: one protein, many targets

Tumour suppressor gene TP53 is frequently mutated in cancer, and therapeutic strategies to restore the functionality of p53 in tumours have been pursued for decades without success. This Review discusses the promising approaches towards p53-based therapy that have emerged in recent years.

Ori Hassin
Moshe Oren
Reviews10 Oct 2022
Nature Reviews Drug Discovery

Volume: 22, P: 127-144
Downregulation of β-catenin by p53 involves changes in the rate of β-catenin phosphorylation and Axin dynamics

Elina Levina
Moshe Oren
Avri Ben-Ze'ev
Research05 Apr 2004
Oncogene

Volume: 23, P: 4444-4453
Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop

G Blandino
W Deppert
M Oren
News & Views18 Nov 2011
Cell Death & Differentiation

Volume: 19, P: 180-183
CKIα ablation highlights a critical role for p53 in invasiveness control

This study shows, via a mouse model of intestinal cancer, that in the absence of CKIα, the loss of p53 dramatically enhances tumour progression and metastasis. p53 is shown to normally limit cancer cell invasion via the regulation of p21 and a set of invasion genes that include Prox1. This study adds important insights to the emerging picture that during tumour development the p53 tumour suppressor gene not only controls cell death and proliferation but also metastasis.

Ela Elyada
Ariel Pribluda
Yinon Ben-Neriah
Research16 Feb 2011
Nature

Volume: 470, P: 409-413
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Oren Pasvolsky
Moshe Yeshurun
Anita D’Souza
Research04 Oct 2021
Bone Marrow Transplantation

Volume: 57, P: 31-37
Simultaneous measurement of genome-wide transcription elongation speeds and rates of RNA polymerase II transition into active elongation with 4sUDRB-seq

4sUDRB-seq is a genome-wide method for measuring the transcription rate of actively transcribed genes. It can provide information on the speed of elongation and on the rate at which RNA polymerase II makes the transition into active elongation.

Gilad Fuchs
Yoav Voichek
Moshe Oren
Protocols26 Mar 2015
Nature Protocols

Volume: 10, P: 605-618
ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1

High concentrations of some types of plasma lipoproteins, such as low-density lipoprotein, promote atherosclerosis and a wide range of vascular-related diseases. These pathogenic lipoproteins have in common the protein component apolipoprotein B. Through study of the effects of modulating lipoprotein levels in experiments involving zebrafish, mice and cultured human endothelial cells, Inbal Avraham-Davidi et al. uncover a potentially deleterious role of apolipoprotein B–containing lipoproteins as direct inhibitors of the angiogenic behavior of vascular endothelial cells.

Inbal Avraham-Davidi
Yona Ely
Karina Yaniv
Research13 May 2012
Nature Medicine

Volume: 18, P: 967-973
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey

Moshe Yeshurun
Uri Rozovski
Rafael de la Camara
Research18 Jan 2023
Bone Marrow Transplantation

Volume: 58, P: 414-423
Decision making by p53: life, death and cancer

M Oren
Reviews28 Apr 2003
Cell Death & Differentiation

Volume: 10, P: 431-442

Previous page
page 1
page 2
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2025 Springer Nature Limited